Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 103 articles:
HTML format
Text format



Single Articles


    October 2019

  1. Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus.
    N Engl J Med. 2019;381:1598.
    PubMed     Text format    


  2. BROWN SA, Kovatchev BP, Raghinaru D, Lum JW, et al
    Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
    N Engl J Med. 2019 Oct 16. doi: 10.1056/NEJMoa1907863.
    PubMed     Text format     Abstract available


    September 2019
  3. REAVEN PD, Hayward RA, Zhou J
    Intensive Glucose Control and Type 2 Diabetes - 15 Years On. Reply.
    N Engl J Med. 2019;381:1293.
    PubMed     Text format    


  4. CERIELLO A, Nicolucci A
    Intensive Glucose Control and Type 2 Diabetes - 15 Years On.
    N Engl J Med. 2019;381:1292-1293.
    PubMed     Text format    


  5. JARDINE MJ, Mahaffey KW, Perkovic V
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.
    N Engl J Med. 2019;381:1089-1090.
    PubMed     Text format    


  6. POST A, Eisenga MF, Bakker SJL
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1089.
    PubMed     Text format    


  7. LIMA JG, Santos MC, Simas BC
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1088-1089.
    PubMed     Text format    


  8. ISREB M, Al-Makki A, Buatois E
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1088.
    PubMed     Text format    


  9. LESLIE BR, Gerwin LE
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1087-1088.
    PubMed     Text format    


  10. MAKRIDES M, Best K, Yelland L, McPhee A, et al
    A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery.
    N Engl J Med. 2019;381:1035-1045.
    PubMed     Text format     Abstract available


  11. STEG PG, Bhatt DL, Simon T, Fox K, et al
    Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMoa1908077.
    PubMed     Text format     Abstract available


  12. BATES ER
    Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes.
    N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMe1910813.
    PubMed     Text format    


    June 2019
  13. HUSAIN M, Birkenfeld AL, Donsmark M, Dungan K, et al
    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2019 Jun 11. doi: 10.1056/NEJMoa1901118.
    PubMed     Text format     Abstract available


  14. HEROLD KC, Bundy BN, Long SA, Bluestone JA, et al
    An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMoa1902226.
    PubMed     Text format     Abstract available


  15. ROSEN CJ, Ingelfinger JR
    Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMe1907458.
    PubMed     Text format    


  16. PITTAS AG, Dawson-Hughes B, Sheehan P, Ware JH, et al
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMoa1900906.
    PubMed     Text format     Abstract available


  17. WEXLER DJ
    D2d - No Defense against Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMe1906815.
    PubMed     Text format    


  18. LIPSKA KJ, Laiteerapong N
    Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial.
    N Engl J Med. 2019;380:2266-2267.
    PubMed     Text format    


  19. REAVEN PD, Emanuele NV, Wiitala WL, Bahn GD, et al
    Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
    N Engl J Med. 2019;380:2215-2224.
    PubMed     Text format     Abstract available


    May 2019
  20. INGE TH, Courcoulas AP, Jenkins TM, Michalsky MP, et al
    Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults.
    N Engl J Med. 2019;380:2136-2145.
    PubMed     Text format     Abstract available


  21. WIVIOTT SD, Raz I, Sabatine MS
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2019;380:1881-1882.
    PubMed     Text format    


  22. AKINCI B
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1881.
    PubMed     Text format    


  23. BAGLIONI P
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1880-1881.
    PubMed     Text format    


    April 2019
  24. TAMBORLANE WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, et al
    Liraglutide in Children and Adolescents with Type 2 Diabetes.
    N Engl J Med. 2019 Apr 28. doi: 10.1056/NEJMoa1903822.
    PubMed     Text format     Abstract available


  25. ROGERS KK
    Diabetes and Disclosure.
    N Engl J Med. 2019;380:1495-1497.
    PubMed     Text format    


  26. INGELFINGER JR, Rosen CJ
    Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMe1904740.
    PubMed     Text format    


  27. PERKOVIC V, Jardine MJ, Neal B, Bompoint S, et al
    Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744.
    PubMed     Text format     Abstract available


    March 2019
  28. FERENCE BA, Ray KK, Catapano AL, Ference TB, et al
    Mendelian Randomization Study of ACLY and Cardiovascular Disease.
    N Engl J Med. 2019;380:1033-1042.
    PubMed     Text format     Abstract available


    February 2019
  29. RIDKER PM, Everett BM, Pradhan A, MacFadyen JG, et al
    Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    N Engl J Med. 2019;380:752-762.
    PubMed     Text format     Abstract available


    January 2019
  30. KARANDINOS G, Bourgois P
    The Structural Violence of Hyperincarceration - A 44-Year-Old Man with Back Pain.
    N Engl J Med. 2019;380:205-209.
    PubMed     Text format    


    December 2018
  31. RAWSHANI A, Rawshani A, Gudbjornsdottir S
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2575.
    PubMed     Text format    


  32. HU Y, Hu FB, Sun Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574-2575.
    PubMed     Text format    


  33. KANNT A
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574.
    PubMed     Text format    


  34. MANSI IA
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573-2574.
    PubMed     Text format    


  35. FAN T, Yang S, Geng Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573.
    PubMed     Text format    


  36. ANKER MS, Kalantar-Zadeh K, Doehner W
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2573.
    PubMed     Text format    



  37. Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2575.
    PubMed     Text format    


    November 2018
  38. MORA CARPIO AL, Stempel JM
    Pneumococcal Bacteremia and Meningitis.
    N Engl J Med. 2018;379:2063.
    PubMed     Text format    


  39. MARCHAND L
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed     Text format    


  40. LAL A, Katta SR, Trivedi N
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed     Text format    


  41. BALLY L, Thabit H, Hovorka R
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970-1971.
    PubMed     Text format    


  42. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389.
    PubMed     Text format     Abstract available


  43. MEKAHLI D, Jouret F
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-5.
    PubMed     Text format    


  44. ROBERTSON GL
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed     Text format    


  45. SPITAL A
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed     Text format    



  46. Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-1786.
    PubMed     Text format    


  47. DOWNING NS, McMullan CJ, Rennke HG, Levy BD, et al
    Complements from the Lung.
    N Engl J Med. 2018;379:1767-1773.
    PubMed     Text format    


    September 2018

  48. Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-1184.
    PubMed     Text format    


  49. RUSSELL MJ, Kanthimathinathan HK
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1183.
    PubMed     Text format    


  50. WHITE PC
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1182-3.
    PubMed     Text format    


  51. KAMEL KS, Carlotti APCP, Halperin ML
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-2.
    PubMed     Text format    


    August 2018

  52. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804989.
    PubMed     Text format     Abstract available



  53. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988.
    PubMed     Text format     Abstract available


  54. BOHULA EA, Wiviott SD, McGuire DK, Inzucchi SE, et al
    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1808721.
    PubMed     Text format     Abstract available


  55. TRIPATHY K
    Asteroid Hyalosis.
    N Engl J Med. 2018;379:e12.
    PubMed     Text format    


  56. SCHROEDER SA
    Heavier but Healthier - Diabetes and Smoking Cessation.
    N Engl J Med. 2018;379:684-685.
    PubMed     Text format    


  57. HU Y, Zong G, Liu G, Wang M, et al
    Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.
    N Engl J Med. 2018;379:623-632.
    PubMed     Text format     Abstract available


  58. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Text format     Abstract available


  59. BALLY L, Thabit H, Hartnell S, Andereggen E, et al
    Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:547-556.
    PubMed     Text format     Abstract available


  60. FENSKE W, Refardt J, Chifu I, Schnyder I, et al
    A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:428-439.
    PubMed     Text format     Abstract available


  61. ROSEN CJ, Ingelfinger JR
    A Reliable Diagnostic Test for Hypotonic Polyuria.
    N Engl J Med. 2018;379:483-484.
    PubMed     Text format    


    June 2018
  62. CAN B, Can B
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    


  63. CADWELL JB, Shukla AP
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    



  64. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537-2538.
    PubMed     Text format    


  65. SPERLING MA
    Fluid Composition, Infusion Rate, and Brain Injury in Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2336-2338.
    PubMed     Text format    


  66. KUPPERMANN N, Ghetti S, Schunk JE, Stoner MJ, et al
    Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2275-2287.
    PubMed     Text format     Abstract available


    April 2018
  67. BJERREGAARD LG, Jensen BW, Angquist L, Osler M, et al
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:1302-1312.
    PubMed     Text format     Abstract available


    March 2018
  68. HUSEBYE ES, Anderson MS, Kampe O
    Autoimmune Polyendocrine Syndromes.
    N Engl J Med. 2018;378:1132-1141.
    PubMed     Text format    


  69. PAWAR AS, Kattah AG
    Lithium-Induced Nephropathy.
    N Engl J Med. 2018;378:1042.
    PubMed     Text format    


  70. KHOO TK, Olson KM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  71. DOUMAS M, Imprialos KP, Stavropoulos K
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  72. CONTE C, Secchi A, Napoli N
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    


  73. GOGTAY NJ, Bose D, Thatte UM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    



  74. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966-968.
    PubMed     Text format    


    February 2018
  75. FLYNN JT
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:580.
    PubMed     Text format    


  76. MEI ZB, Xiao Y
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    


  77. JONNALAGADDA VG, Metety VK
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    



  78. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579-581.
    PubMed     Text format    


    January 2018
  79. AGARWAL A
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:302.
    PubMed     Text format    


  80. CEREDA E
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301-2.
    PubMed     Text format    


  81. DI BELLA S, Monticelli J, Luzzati R
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301.
    PubMed     Text format    


    December 2017
  82. IMPRIALOS KP, Stavropoulos K, Doumas M
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


  83. HOLMAN RR, Bethel MA, Hernandez AF
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


    November 2017
  84. THORNTON SN, Regnault V, Lacolley P
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196-7.
    PubMed     Text format    


  85. IMPRIALOS KP, Stavropoulos K, Doumas M
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196.
    PubMed     Text format    


  86. GULLI G
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-6.
    PubMed     Text format    


  87. TONNEIJCK L, van Raalte DH, Muskiet MHA
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195.
    PubMed     Text format    



  88. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-2199.
    PubMed     Text format    


  89. DE BOER IH
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2198.
    PubMed     Text format    



  90. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-2099.
    PubMed     Text format    


  91. RAJAGOPALAN S, Brook R
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098-9.
    PubMed     Text format    


  92. FERNANDEZBALSELLS MM, Sojo-Vega L, Ricart-Engel W
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098.
    PubMed     Text format    


  93. BAGLIONI P
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-8.
    PubMed     Text format    


  94. PERFETTI R
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995.
    PubMed     Text format    


  95. TAYEK JA, Danese PNN, Smith MS
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994-5.
    PubMed     Text format    


  96. OGUNSAKIN AA, Jain N, Dagogo-Jack S
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994.
    PubMed     Text format    



  97. Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995-1996.
    PubMed     Text format    


  98. MARCOVECCHIO ML, Chiesa ST, Bond S, Daneman D, et al
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2017;377:1733-1745.
    PubMed     Text format     Abstract available


    October 2017
  99. MATSUO T, Ishii N
    Acute Esophageal Necrosis.
    N Engl J Med. 2017;377:1378.
    PubMed     Text format    


    September 2017
  100. ADAMS TD, Davidson LE, Litwin SE, Kim J, et al
    Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
    N Engl J Med. 2017;377:1143-1155.
    PubMed     Text format     Abstract available


  101. HOLMAN RR, Bethel MA, Mentz RJ, Thompson VP, et al
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017 Sep 14. doi: 10.1056/NEJMoa1612917.
    PubMed     Text format     Abstract available


  102. GARG SK, Henry RR, Banks P, Buse JB, et al
    Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337.
    PubMed     Text format     Abstract available


  103. NATHAN DM
    Adjunctive Treatments for Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMe1711296.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: